Cellectar Biosciences, INC

Cellectar Biosciences stockholders approved an amendment to the 2021 Stock Incentive Plan, increasing the share reserve by 2 million shares and ratifying the appointment of Deloitte & Touche LLP.

Cellectar Biosciences announces the departure of Dr. Stefan D. Loren from its Board of Directors and the appointment of Andrew Gu, nominated by Nantahala Capital Management, LLC.

Cellectar Biosciences announced positive Q1 2026 financial results, positive follow-on data for iopofosine I 131, and secured up to $140 million in financing.

Cellectar Biosciences announced a registered direct offering and concurrent private placement raising approximately $35 million to fund its Phase 3 trial for iopofosine I 131.

Cellectar Biosciences announced its 2025 financial results, showcasing significant pipeline advancements and a reduced net loss, while addressing future funding needs.

Cellectar Biosciences reports Q3 2025 financial results, advances regulatory strategy for iopofosine I-131 in Europe, and progresses its radioconjugate pipeline.

Cellectar Biosciences reports Q1 2026 results with reduced R&D expenses, increased manufacturing costs, and a significant financing round, while advancing its iopofosine I 131 program.

Cellectar Biosciences reported significantly reduced net losses and R&D expenses for the nine months ended September 30, 2025, while advancing its lead drug candidate, iopofosine I 131, with FDA Breakthrough Therapy Designation and positive EMA guidance for Waldenstrom macroglobulinemia.

Cellectar Biosciences reported a reduced net loss in Q2 2025, driven by lower R&D and G&A expenses, while announcing a strategic review and Breakthrough Therapy Designation for iopofosine I 131, but faces significant going concern doubts due to limited cash.

Cellectar Biosciences reports Q1 2025 results with a net loss of $6.6 million and explores strategic alternatives amid going concern uncertainties, despite positive clinical data from its CLOVER-WaM study.

Cellectar Biosciences announced its third quarter 2024 financial results, highlighting clinical trial progress and a restatement of prior financial statements due to accounting errors.

Cellectar Biosciences' second quarter 2024 results show increased research and development spending, a net loss, and a strengthened cash position due to warrant exercises.

Cellectar Biosciences filed an amendment to its 2025 Annual Report to provide required Part III disclosures.

Cellectar Biosciences reports significant losses and a going concern warning for 2025, despite positive clinical data for iopofosine I 131 and other PDC programs.

Cellectar Biosciences' 2024 10-K filing details the company's focus on developing phospholipid drug conjugates (PDCs) for targeted cancer treatment and provides an update on its clinical programs and financial status.

Cellectar Biosciences has restated its financial statements for fiscal years 2022 and 2023 due to accounting errors related to warrants and preferred stock, leading to material weaknesses in internal controls.

Cellectar Biosciences has filed an amendment to its annual report on Form 10-K to include previously omitted exhibits and correct a minor error.

Cellectar Biosciences' pivotal Phase 2 study of iopofosine in relapsed/refractory Waldenstrom's macroglobulinemia met its primary endpoint with a 61% major response rate.

Cellectar Biosciences files an amendment to a Form 4 to correct the exercise price of a stock option granted to consultant Loren Stefan.

Cellectar Biosciences CFO Chad Kolean was granted stock options for 92,000 shares, contingent on stockholder approval which was obtained on July 7, 2026.

Cellectar Biosciences Director Frederick W. Driscoll acquired 25,000 stock options with an exercise price of $2.70, vesting fully on July 7, 2027.

Director Asher Chanan-Khan acquired 25,000 stock options in Cellectar Biosciences, Inc. (CLRB) with an exercise price of $2.70, vesting in full on July 7, 2027.

Cellectar Biosciences, Inc. reports the grant of stock options to President & CEO James V. Caruso, contingent on stockholder approval.

Cellectar Biosciences, Inc. reports that Director Andrew Gu acquired 25,000 stock options with an exercise price of $2.70, vesting in full on July 7, 2027.

Cellectar Biosciences announces its 2026 Annual Meeting of Stockholders to vote on director elections, equity plan expansion, and warrant exercise approvals.

Cellectar Biosciences, Inc. filed a supplement to its proxy statement to include an amendment for a proposed reverse stock split at a ratio between 1-for-10 and 1-for-30, to be voted on at its 2025 Annual Meeting of Stockholders.

Cellectar Biosciences is holding its annual stockholder meeting on June 13, 2025, to vote on director elections, auditor ratification, a potential reverse stock split, executive compensation, and meeting adjournment if necessary.

Cellectar Biosciences is seeking stockholder approval for a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.

Cellectar Biosciences issues a supplement to its proxy statement to correct information regarding virtual meeting access for the upcoming Annual Meeting of Stockholders on June 14, 2024.

Cellectar Biosciences announces its 2024 Annual Meeting of Stockholders will be held virtually on June 14, 2024, to vote on director elections, stock incentive plan increase, auditor ratification, and executive compensation.

Cellectar Biosciences has filed an amendment to its registration statement to facilitate the resale of up to 51,998,413 shares of common stock by selling stockholders.

Cellectar Biosciences, Inc. has filed a Form S-1 registration statement to allow selling stockholders to resell up to 51,206,051 shares of common stock.

Cellectar Biosciences, Inc. filed an S-1 registration statement for the resale of up to 2,096,188 shares of common stock by selling stockholders, following a recent warrant inducement transaction that generated $5.8 million in gross proceeds.

Cellectar Biosciences, a late-stage clinical biopharmaceutical company, has filed an S-1/A registration statement for a public offering of up to 755,667 Class A or Class B Units to raise approximately $5.0 million, primarily to advance its cancer drug pipeline, despite facing significant financial constraints and a recent reverse stock split.

Cellectar Biosciences, a late-stage clinical biopharmaceutical company, has filed an S-1 registration statement for a public offering of up to 755,667 Class A or Class B Units to raise approximately $5.0 million, while acknowledging that these proceeds will not be sufficient to fund a key clinical trial through data readout and raising substantial doubt about its ability to continue as a going concern.

Cellectar Biosciences is registering for resale up to 19,221,348 shares of its common stock by selling stockholders after a warrant inducement transaction.

Empery Asset Management, LP and Ryan M. Lane have jointly filed a Schedule 13G, reporting beneficial ownership of 9.99% of Cellectar Biosciences, Inc. common stock, including shares issuable upon warrant exercise.

Janus Henderson Group plc has filed a Schedule 13G reporting beneficial ownership of 9.99% of Cellectar Biosciences, Inc. common stock.

Stonepine Capital Management has reported a 9.9% beneficial ownership stake in Cellectar Biosciences following recent equity and warrant issuances.

Rosalind Advisors and affiliated funds disclose a 5.5% beneficial ownership in Cellectar Biosciences, Inc., factoring in conversion limitations.

Hexstone Capital LLC and Brendan O'Neil have filed an amendment indicating they are no longer beneficial owners of more than 5% of Cellectar Biosciences, Inc. common stock.

Bleichroeder LP, Bleichroeder Holdings LLC, and Andrew Gundlach have jointly reported a 6.08% beneficial ownership stake in Cellectar Biosciences, Inc., totaling 200,000 common shares.